[1]陈运龙,刘川,刘小燕,等.脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析[J].第三军医大学学报,2018,40(12):1136-1141.
 CHEN Yunlong,LIU Chuan,LIU Xiaoyan,et al.Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients[J].J Third Mil Med Univ,2018,40(12):1136-1141.
点击复制

脂蛋白相关磷脂酶A2、糖化血红蛋白水平与糖尿病患者冠脉病变程度的相关性分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第12期
页码:
1136-1141
栏目:
临床医学
出版日期:
2018-06-30

文章信息/Info

Title:
Correlation of lipoprotein-associated phospholipase A2 and hemoglobin A1c levels with severity of coronary artery disease in diabetic patients
作者:
陈运龙刘川刘小燕郭志念翁显贵王蓉王江
陆军军医大学(第三军医大学)第二附属医院心血管内科, 全军心血管病研究所
Author(s):
CHEN Yunlong LIU Chuan LIU Xiaoyan GUO Zhinian WENG Xiangui WANG Rong WANG Jiang

Department of Cardiology, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, China

关键词:
冠心病糖尿病 脂蛋白相关磷脂酶A2 糖化血红蛋白
Keywords:
coronary heart disease diabetes mellitus lipoprotein-associated phospholipase A2 hemoglobin A1c
分类号:
R446.11;R543.3;R587.2
文献标志码:
A
摘要:

目的探讨脂蛋白相关磷脂酶A2(lipoprotein-associated phospholipase A2,Lp-PLA2)、糖化血红蛋白(HbA1c)水平与糖尿病患者冠脉病变程度的相关性。方法选取2017年7月至12月在陆军军医大学(第三军医大学)第二附属医院心血管内科住院患者241例;按冠脉狭窄程度及糖尿病病史分为冠心病组(42例)、糖尿病组(34例)、糖尿病合并冠心病组(127例)、正常对照组(38例)。按左心室射血分素(LVEF)结果分为LVEF<50%组(91例)和LVEF≥50%(150例)。检测循环LpPLA2和HbA1c水平并进行统计学分析。结果糖尿病合并冠心病组LpPLA2水平显著高于糖尿病组和正常对照组(P<0.05);HbA1c在糖尿病合并冠心病组显著高于冠心病组和正常对照组(P<0.05)。多元线性回归分析LpPLA2、HbA1c与冠脉狭窄程度(Gensini积分)正相关(r值:0.189、0.138,P<0.05)。多因素Logistic回归分析LpPLA2、HbA1c为冠脉狭窄程度的独立危险因素(OR值:1.012、0.097、P<0.05)。LVEF<50%组LpPLA2水平显著高于LVEF≥50%组(P<0.05);HbA1c水平两组间比较差异无统计学意义(P>0.05)。结论糖尿病合并冠心病患者循环Lp-PLA2和HbA1c水平明显升高且与冠状动脉狭窄程度呈正相关,二者联合检测对预测糖尿病患者冠脉病变程度有较好的临床价值。

Abstract:

ObjectiveTo explore the correlation of circulating lipoproteinassociated phospholipase A2 (LpPLA2) and hemoglobin A1c (HbA1c) levels with the severity of coronary artery stenosis in patients with type 2 diabetes mellitus (T2DM). MethodsA total of 241 inpatients with suspected coronary artery disease (CHD) admitted in our department between July, 2017 and December, 2017 were enrolled in this study. According to the findings in coronary angiography, the patients were divided into CHD, T2DM, CHD with T2DM and healthy control groups. The patients were also stratified according to their left ventricular ejection fraction (LVEF) into LVEF <50% group and LVEF≥50% group. For all the participants, circulating HbA1c level was determined with chemiluminescence detection and LpPLA2 level with enzymelinked immunosorbent assay (ELISA). ResultsLpPLA2 level was significantly higher in diabetic patients with CHD than in those with T2DM and the healthy control subjects (P<0.05). The diabetic patients with CHD also showed a significantly higher level of HbA1c than those with CHD and the control subjects (P<0.05). Multivariate linear regression analysis showed that LpPLA2 (r=0.189, P<0.05) and HbA1c (r=0.138, P<0.05) levels were both positively correlated with the severity of coronary stenosis (Gensini score). Multivariate logistic regression analysis identified LpPLA2 (OR=1.012, P<0.05) and HbA1c (OR=0.097, P<0.05) as independent risk factors for coronary stenosis. The patients with a LVEF <50% had a significantly higher LpPLA2 level than those with a LVEF ≥50% (P<0.05), but their HbA1c level did not differ significantly (P>0.05). ConclusionIn diabetic patients with CHD, LpPLA2 and HbA1c levels are positively correlated with the severity of coronary artery stenosis, and the combined detection of LpPLA2 and HbA1c can be clinically informative for predicting the severity of coronary artery stenosis.
 

参考文献/References:

[1]SOFOGIANNI A, ALKAGIET S, TZIOMALOS K. Lipoproteinassociated phospholipase A2 and coronary heart disease[J]. Curr Pharm Des, 2018, 10. DOI: 10.2174/1381612 824666180111110550.[Epub ahead of print]
[2]GARG P K, MCCLELLAND R L, JENNY N S, et al. Lipoproteinassociated phospholipase A2 and risk of incident cardiovascular disease in a multiethnic cohort: The multi ethnic study of atherosclerosis[J]. Atherosclerosis, 2015, 241(1): 176-182. DOI: 10.1016/j.atherosclerosis.2015.05.006.
[3]LI D, ZHAO L, YU J, et al. Lipoproteinassociated phospholipase A2 in coronary heart disease: review and metaanalysis[J]. Clin Chim Acta, 2017, 465: 22-29. DOI: 10.1016/j.cca.2016.12.006.
[4]BALLANTYNE C M, HOOGEVEEN R C, BANG H, et al. Lipoproteinassociated phospholipase A2, highsensitivity Creactive protein, and risk for incident coronary heart disease in middleaged men and women in the atherosclerosis risk in communities (ARIC) study[J]. Circulation, 2004, 109(7): 837-842. DOI: 10.1161/01.CIR.0000116763.91992.F1.
[5]DANIELS L B, LAUGHLIN G A, SARNO M J, et al. Lipoproteinassociated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study[J]. J Am Coll Cardiol, 2008, 51(9): 913-919. DOI: 10. 1016/j.jacc.2007.10.048.
[6]YANG L, LIU Y, WANG S, et al. Association between LpPLA2 and coronary heart disease in Chinese patients[J]. J Int Med Res, 2017, 45(1): 159-169. DOI: 10.1177/030 0060516678145.
[7]BENDERLY M, SAPIR B, KALTERLEIBOVICI O, et al. Lipoproteinassociated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease[J]. Biomarkers, 2017, 22(34): 219-224. DOI: 10.3109/1354750X.2016.1171910.
[8]ARSENAULT B J, KOHLI P, LAMBERT G, et al. Emerging cardiovascular disease biomarkers and incident diabetes mellitus risk in statintreated patients with coronary artery disease (from the treating to new targets [TNT]study)[J]. Am J Cardiol, 2016, 118(4): 494-498. DOI: 10.1016/j.amjcard.2016.05.044.
[9]MAYER O J R, SEIDLEROVá J, FILIPOVSKY J, et al. Unexpected inverse relationship between impaired glucose metabolism and lipoproteinassociated phospholipase A2 activity in patients with stable vascular disease[J]. Eur J Intern Med, 2014, 25(6): 556-560. DOI: 10.1016/j.ejim.2014.05.010.
[10]GARG S, MADHU S V, SUNEJA S. Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type2 diabetes mellitus[J]. Indian J Med Res, 2015, 141(1): 107-114. DOI: 10.4103/09715916.154512.
[11]SEYFARTH J, REINEHR T, HOYER A, et al. Lipoproteinassociated phospholipase A2 activity in obese adolescents with and without type 2 diabetes[J]. J Inherit Metab Dis, 2018, 41(1): 73-79. DOI: 10.1007/s1054501701000.
[12]Kotani K.Plasma lipoproteinassociated phospholipase A2 levels correlated with the cardioankle vascular index in longterm type 2 diabetes mellitus patients[J]. Int J Mol Sci, 2016, 17(5): pii: E634. DOI: 10.3390/ijms17050634.
[13]JIANG J, ZHAO L, LIN L, et al. Postprandial blood glucose outweighs fasting blood glucose and HbA1c in screening coronary heart disease[J]. Sci Rep, 2017, 7(1): 14212. DOI: 10.1038/s4159801714152y.
[14]ERTEM A G, BAGˇBANCI H, KILI H, et al. Relationship between HbA1c levels and coronary artery severity in nondiabetic acute coronary syndrome patients[J]. Turk Kardiyol Dern Ars, 2013, 41(5): 389-395.
[15]WHITE H D, SIMES J, STEWART R A, et al. Changes in lipoproteinassociated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the longterm intervention with pravastatin in ischemic disease study[J]. J Am Heart Assoc, 2013, 2(5): e000360. DOI: 10.1161/JAHA.113.000360.
[16]SCHAEFER E J, MCNAMARA J R, ASZTALOS B F, et al. Effects of atorvastatin versus other statins on fasting and postprandial Creactive protein and lipoproteinassociated phospholipase A2 in patients with coronary heart disease versus control subjects[J]. Am J Cardiol, 2005, 95(9): 1025-1032. DOI: 10.1016/j.amjcard.2005.01.023.
[17]STABILITY INVESTIGATORS, WHITE H D, HELD C, et al. Darapladib for preventing ischemic events in stable coronary heart disease[J]. N Engl J Med, 2014, 370(18): 1702-1711. DOI: 10.1056/NEJMoa1315878.
[18]O’DONOGHUE M L, BRAUNWALD E, WHITE H D, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLIDTIMI 52 randomized clinical trial[J]. JAMA, 2014, 312(10): 1006-1015. DOI: 10.1001/jama.2014.11061.

相似文献/References:

[1]牟海刚,古平.莱姆病伴直立性低血压误诊为糖尿病心血管自主神经病1例[J].第三军医大学学报,2012,34(15):1542.
[2]周厚地,童强,段炼,等.胃大部切除术致糖尿病患者反复低血糖1例[J].第三军医大学学报,2012,34(17):1753.
[3]吴艳,王毅,曾绍凡,等.老年2型糖尿病瘦素、骨密度变化及相关因素的研究[J].第三军医大学学报,2007,29(22):2188.
 WU Yan,WANG Yi,ZENG Shao-fan,et al.Bone density, leptin level and other related factors in elder patients with type 2 diabetes[J].J Third Mil Med Univ,2007,29(12):2188.
[4]李志勤.饮食护理干预对老年糖尿病患者血糖和糖化血红蛋白水平的影响[J].第三军医大学学报,2012,34(20):2130.
[5]徐灵莉,邓本敏,唐玲,等.护理风险管理能有效提高糖尿病合并恶性肿瘤患者的化疗疗效[J].第三军医大学学报,2013,35(04):351.
 Xu Lingli,Deng Benmin,Tang Ling,et al.Risk management of nursing improves chemotherapy efficiency for diabetic patients with malignant tumor[J].J Third Mil Med Univ,2013,35(12):351.
[6]魏平.糖尿病治疗的新趋势及相关热点追踪[J].第三军医大学学报,2012,34(23):2435.
[7]李明秀,王建,樊荣,等.癌症合并糖尿病患者住院期间的营养治疗[J].第三军医大学学报,2007,29(21):2079.
[8]高原,肖谦,赵柯湘,等.替米沙坦对糖尿病大鼠认知功能的保护作用[J].第三军医大学学报,2007,29(15):1514.
 GAO Yuan,XIAO Qian,ZHAO Ke-Xiang,et al.The study of the protection of telmisartan on the cognitive function in diabetic rats[J].J Third Mil Med Univ,2007,29(12):1514.
[9]范伟,杨妤欣,陈隽,等.糖尿病大鼠早期骨微结构改变及其BMP-2基因的表达[J].第三军医大学学报,2007,29(11):1053.
 FAN Wei,YANG Yu-xin,CHEN Juan,et al.Bone microstructure changes and bone BMP-2 expression in rats at early period of diabetes[J].J Third Mil Med Univ,2007,29(12):1053.
[10]杨光玉,卿尚兰,陈英.糖尿病患者根管治疗中疼痛有关因素的临床研究[J].第三军医大学学报,2007,29(10):982.
 YANG Guang-yu,QING Shang-lan,CHEN Ying.Correlation of diabetes mellitus and endodontic interappointment pain[J].J Third Mil Med Univ,2007,29(12):982.

更新日期/Last Update: 2018-07-03